A total of 314 isolates of @entity328 collected by 10 different laboratories were tested for their susceptibility by using a microdilution technique following NCCLS recommendations. The following antibiotics were included: @entity114 , @entity869 , @entity115 , @entity115 / @entity798 , @entity5504 , @entity2261 , @entity3524 , @entity2892 , @entity2177 , @entity10127 , @entity800 , @entity2929 , @entity4581 , @entity4580 , @entity9386 , @entity3402 and @entity803 . The insusceptibility rate (IR) to @entity114 was 21.0% [10.8% intermediate (> or = 0.12-1 microgram/mL) and 10.2% high-level (> or = 2 micrograms/mL)], to @entity3524 7.3% [3.5% intermediate (> or = 1 microgram/mL) and 3.8% high-level (> or = 2 micrograms/mL)], to @entity2892 3.8% [3.8% intermediate (> or = 0.25-0.5 microgram/mL) and 0% high-level (> or = 1 microgram/mL)], to @entity2177 11.2% [8.3% intermediate (2 micrograms/mL) and 3.9% high-level (> or = 4 micrograms/mL)], to @entity2929 30.3% [3.5% intermediate (0.5 microgram/mL) and 26.8% high-level (> or = 1 microgram/mL)] and to @entity803 38.5% [0.9% intermediate (4 micrograms/mL) and 37.6% high-level (> or = 8 micrograms/mL)]. No decreased susceptibility was found for @entity10127 (> or = 0.5 microgram/mL). This compound was the most active with MIC50, MIC90 and an IR of 0.015 microgram/mL, 0.03 microgram/mL and 0% respectively, followed by @entity115 / @entity798 , @entity115 and @entity2892 (MIC50, MIC90 and IR: 0.015 microgram/mL, 1 microgram/mL, 1.6%/0.015 microgram/mL, 1 microgram/mL, 1.9%/0.008 microgram/mL, 0.12 microgram/mL, 3.8% respectively). Compared to the 1999 surveillance, @entity114 and @entity803 -insusceptibility increased with 4.9% and 15.6% respectively, while @entity3524 , @entity2929 and @entity2177 insusceptibility decreased with 5.4%, 5.8% and 4.4% respectively. MICs of all beta-lactams rose with those of @entity114 for @entity114 -insusceptible isolates. @entity2892 , @entity3524 , @entity115 and @entity115 / @entity798 were generally 4, 2, 1 and 1 doubling dilutions respectively more potent than @entity114 on these isolates while @entity869 , @entity2261 and cefactor were generally 1, 2 and 4 dilutions respectively [table: see text] less potent. Most @entity114 -insusceptible isolates remained fully susceptible to @entity115 / @entity798 (92.4%), @entity115 (90.9%) and @entity2892 (81.8%). @entity2929 - @entity803 insusceptibility was the most common resistance phenotype (14.3%). Three- and four-fold resistance was found in 12.4% and 1.6% respectively of the isolates. Most @entity114 -insusceptible isolates were of capsular types 14 (22.7%), 23 (21.2%), 6 (18.2%), 9 (13.6%) and 19 (12.1%).

Surveillance of antibiotic resistance in clinical isolates of XXXX collected in Belgium during winter 2000-2001.

@entity2261 :: ('MESH:D002444', 'Chemical') :: ['cefuroxime'] @entity2892 :: ('MESH:D015378', 'Chemical') :: ['imipenem', 'Imipenem'] @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin'] @entity5504 :: ('MESH:D002433', 'Chemical') :: ['cefaclor'] @entity10127 :: ('MESH:C103274', 'Chemical') :: ['gemifloxacin'] @entity114 :: ('MESH:D010406', 'Chemical') :: ['penicillin'] @entity4581 :: ('MESH:D017291', 'Chemical') :: ['clarithromycin'] @entity2929 :: ('MESH:D004917', 'Chemical') :: ['erythromycin', 'Erythromycin'] @entity2177 :: ('MESH:D002939', 'Chemical') :: ['ciprofloxacin'] @entity4580 :: ('MESH:D017963', 'Chemical') :: ['azithromycin'] @entity798 :: ('MESH:D019818', 'Chemical') :: ['clavulanate'] @entity3524 :: ('MESH:D002439', 'Chemical') :: ['cefotaxime'] @entity800 :: ('MESH:D015242', 'Chemical') :: ['levofloxacin'] @entity869 :: ('MESH:D000667', 'Chemical') :: ['ampicillin'] @entity9386 :: ('MESH:D015644', 'Chemical') :: ['miocamycin'] @entity803 :: ('MESH:D013752', 'Chemical') :: ['tetracycline'] @entity328 :: ('1313', 'Species') :: ['Streptococcus pneumoniae'] @entity3402 :: ('MESH:D002981', 'Chemical') :: ['clindamycin']
@entity328 :: (1313,Species) :: ['Streptococcus pneumoniae']
